The acquisition will enhance Paramit’s capabilities and market leadership in life sciences and in-vitro diagnostics
Paramit Corporation has entered into a definitive agreement to be acquired by the Tecan Group for a total purchase consideration of $1.0 billion (CHF 920 million). Based in Maennedorf, Switzerland, Tecan is a leading global provider of laboratory instruments and solutions in life science research and clinical diagnostics. The acquisition will enhance Paramit’s capabilities and market leadership in life sciences and in-vitro diagnostics (IVD), significantly accelerate Tecan’s entry into medical devices and expand the combined platform’s total addressable market to serve its customers around the world. Since 2011, Paramit Corporation has been privately held by Altaris Capital Partners, a healthcare-dedicated investment firm based in New York, NY.
The transaction will create a combined global platform with world-class design, development and manufacturing capabilities and scale to provide unparalleled support to customers in the fastest-growing segments of healthcare. In addition, Paramit will be able to enhance Tecan’s service offering for its existing OEM customer base and leverage Tecan’s strong commercial channels to further expand Paramit’s reach in the European and Asian markets, including China, and beyond.
“It has been an incredible journey establishing Paramit as a global leader in the life sciences and medical device industries alongside Altaris. We are incredibly proud of the organisation we have built together and look forward to our future with Tecan,” said Billoo Rataul, CEO, Paramit.
“Combining Paramit’s leading design and manufacturing expertise with Tecan’s strengths is the next logical step for our growing business. Becoming part of the Tecan Group will take our industry-leading offering to new customers in expanding markets. It will enable us to further develop our expertise in life sciences and clinical diagnostics and address an extended range of scientific applications. Tecan’s commitment to our strategic position in medical devices will also boost our growth in that sector. Our customers stand to gain from the combined supply chain depth and Tecan’s broad expertise in the design and manufacturing of solutions for highly regulated environments. We passionately share Tecan’s customer-focused culture and its mission to contribute to the quality of life of humankind. We are therefore excited to begin this new chapter in the development of our organisation.”
Dr Achim von Leoprechting, CEO, Tecan, commented, “Tecan will gain a new highly efficient manufacturing capacity in Asia and a strong presence for its OEM business in North America. At the same time, Paramit will gain access to Tecan’s existing sales channels in other parts of the world. These opportunities will help us to broaden our customer base and offering, while further strengthening our ability to serve the healthcare market.”
The transaction is expected to close in the coming months, subject to customary closing conditions. Morgan Stanley & Co acted as financial advisor and Schiff Hardin acted as legal counsel for Paramit.
